GMED Stock Analysis: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$86.91
1.24 (1.45%)
▲
5d:
+1.18%
30d:
+15.23%
90d:
+2.72%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GMED shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GMED shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$129.67
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$80.52
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $86.91, which is considered extended relative to its 30-day fair value range of $77.71 to $85.62. From a valuation perspective, the stock is trading at a discount (Forward PE: 16.2) compared to its historical average (18.2). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMED is in a downtrend. The price is approaching resistance at $88.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMED scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $103.23 (+18.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GMED is in a downtrend. The price is approaching resistance at $88.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMED scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $103.23 (+18.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$77.71 -
$85.62
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
40.4%
Protect Your Profits
Holding GMED? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($103.23)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$77.71 -
$85.62
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.87
(4.5%)
Support & Resistance Levels
Support Level
$81.40
Resistance Level
$88.89
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.20
Wall Street Target
$103.23
(+18.8%)
Revenue Growth (YoY)
5.9%
Earnings Growth (YoY)
-26.2%
Profit Margin
17.0%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
16.2 vs 18.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$83.69
(-4%)
2-Year Target
$80.60
(-7%)
3-Year Target
$77.62
(-11%)
3-Yr Target (if PE normalizes)
(PE: 16→18)
$87.18
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 7.7%)
$134.43
(+55%)
Base:
(SPY PE: 16.2, Growth: 7.7%)
$108.53
(+25%)
Bear:
(PE: 13.8, Growth: 7.7%)
$92.25
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 22.54 | Current EPS (TTM): $3.80
Bull Case
$133.02
(+53%)
Analyst growth 41.2%, PE expands to 24.8
Base Case
$120.93
(+39%)
Market implied 41.2%, PE stable at 22.5
Bear Case
$58.26
(-33%)
Severe decline -20.0%, PE contracts to 19.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.2 to 18.2
Stabilization Target:
$97.62
(+12.3%)
PE Expansion Potential:
+12.3%
Share & Embed Analysis
Last updated: August 24, 2026 7:15 AM ET
Data refreshes hourly during market hours. Next update: 8:15 AM
Data refreshes hourly during market hours. Next update: 8:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
NEUTRAL
Recent Transactions
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 37 SELL |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
